Metoclopramide

Dosage ; Over 15 years: 10mg TID (over 60kg), 5mg TID (under 60kg).

9-14 years:5mg TID (over 30kg). 5-9 years: 2.5mg TID (20-29kg).

3-5 years: 2mg BD or TID (15-19kg). 1-3 years:1mg BD or TID (10-14kg).

Under 1 year: 1mg BD daily dose should. Not to exceed 0.5/kg/day.

Metoclopramide Brands

Brand Name Manufacturer Name Distributor Drug Strength Packaging Formulation Formulation Strength Price
Domide Dawa Limited Dawa Limited 5mg 60ml Syrup per 5ML KES 45.00
Emeton Biodeal Laboratories Ltd. Biodeal Laboratories Ltd. 5mg 60ml Syrup per 5ML KES 60.00
Emeton Biodeal Laboratories Ltd. Biodeal Laboratories Ltd. 10mg 100 doses Tablet per tablet KES 400.00
Gastrolon Efroze Chemical Industries Ltd Njimia Pharmaceuticals Ltd. 10mg 100 Tablet per tablet KES 151
Melasil Laboratory & Allied Ltd. Laboratory & Allied Ltd 10mg 100 Tablet per tablet KES 53.00
Melasil Laboratory & Allied Ltd. Laboratory & Allied Ltd 10mg 1000 Tablet per tablet KES 325.00
Melasil Laboratory & Allied Ltd. Laboratory & Allied Ltd 5mg 1 Injection per vial KES 12.00
Melasil Laboratory & Allied Ltd. Laboratory & Allied Ltd 5mg 100ml Syrup per 5ML KES 32.oo
Metcos Cosmos Limited. Cosmos Limited 10mg 100 Tablet per tablet KES 100.00
Perinorm IPCA Sai Pharmaceuticals Ltd. 5mg 10 Injection per ml KES 146
Primperan Sanofi Aventis Surgipharm Ltd 10mg 20 Tablet per tablet KES 456
Primperan Sanofi Aventis Surgipharm Ltd 5mg 12 Injection per ml KES 435
Cloperan Remedica Ltd. Twokay Chemicals Ltd 10mg 100 Tablet per tablet KES 400.00
Metoclon Indus Pharma Globe Pharmacy Ltd., 10mg 2ml Injection per vial KES 11.70
Metopride Prism Life Sciences Galaxy Pharmaceuticals Ltd 10mg 2ml infusion per ml KES 12.00

Metoclopramide More info

Drug Indication Digestive disorders associated with gastrointestinal stasis, hypomotility, drug induced vomiting, emetic disorders; facilitation of the intestinal intubation in adults and children; stimulation of gastric emptying and intestinal transit of barium in cases where delayed; persistent hiccups.
Precautions Parkinsonism; young patients; concomitant use with medicines that cause extrapyramidal side effects; total daily dose should not exceed 0.5mg/kg BM; prolonged therapy; those at risk of fluid retention; renal impairment; elderly.
Contra-Indications Phaeochromocytoma: may cause a hypertensive crisis; not to be used when stimulation of GI motility might be dangerous (e.g., in case of GI haemorrhage; mechanical obstruction, or perforation); known sensitivity or intolerance to the drug; epileptics or patients receiving other drugs that can cause extrapyramidal reactions.
Side Effects Extrapyramidal effects; CNS effects; GI disturbances; peri-orbital oedema; skin rash; galactorrhoea; gynaecomastia; breast engorgement; impotence; amenorrhoea; tardive dyskinesia; restlessness; drowsiness.
Dosage Over 15 years: 10mg TID (over 60kg), 5mg TID (under 60kg). 9-14 years:5mg TID (over 30kg). 5-9 years: 2.5mg TID (20-29kg). 3-5 years: 2mg BD or TID (15-19kg). 1-3 years:1mg BD or TID (10-14kg). Under 1 year: 1mg BD daily dose should. Not to exceed 0.5/kg/day.
Pregnancy Category Category A1:
Pregnancy Category Description Drugs which have been taken by a sizeable number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted.
Drug Sub-Category Motility stimulants

Dosing: Adult

Gastroesophageal reflux: Oral: 10-15 mg/dose up to 4 times/day 30 minutes before meals or food and at bedtime; single doses of 20 mg are occasionally needed prior to provoking situations. Treatment >12 weeks is not recommended.

Diabetic gastroparesis:

Oral: 10 mg/dose up to 4 times/day 30 minutes before meals or food and at bedtime for 2-8 weeks

I.M., I.V. (for severe symptoms): 10 mg over 1-2 minutes; 10 days of I.V. therapy may be necessary before symptoms are controlled to allow transition to oral administration

Chemotherapy-induced emesis prophylaxis: I.V.: 1-2 mg/kg 30 minutes before chemotherapy and repeated every 2 hours for 2 doses, then every 3 hours for 3 doses (manufacturer labeling); pretreatment with diphenhydramine will decrease risk of extrapyramidal reactions

Alternate dosing: Note: Metoclopramide is considered an antiemetic with a low therapeutic index; use is generally reserved for agents with low emetogenic potential or in patients intolerant/refractory to first line antiemetics.

Low-risk chemotherapy (unlabeled): I.V., Oral: 10-40 mg prior to dose, then every 4-6 hours as needed (NCCN Antiemesis guidelines, v.4.2009)

Breakthrough treatment (unlabeled): I.V., Oral: 10-40 mg every 4-6 hours (NCCN Antiemesis guidelines, v.4.2009)

Delayed-emesis prophylaxis (unlabeled): Oral: 20-40 mg/dose (or 0.5 mg/kg/dose) 2-4 times/day for 3-4 days (in combination with dexamethasone [ASCO guidelines, 2006])

Refractory or intolerant to antiemetics with a higher therapeutic index (unlabeled; Hesketh, 2008):

I.V.: 1-2 mg/kg/dose before chemotherapy and repeat 2 hours after chemotherapy

Oral: 0.5 mg/kg every 6 hours on days 2-4

Postoperative nausea and vomiting prophylaxis: I.M., I.V. (unlabeled route): 10-20 mg near end of surgery. Note: Guidelines discourage use of 10 mg metoclopramide as being ineffective (Gan, 2007); comparative study indicates higher dose (20 mg) may be efficacious (Quaynor, 2002).

Postpyloric feeding tube placement, radiological exam: I.V.: 10 mg as a single dose

Dosing: Pediatric

(For additional information see "Metoclopramide: Pediatric drug information")

Gastroesophageal reflux (unlabeled use): Oral: 0.1-0.2 mg/kg/dose 4 times/day (maximum: 5 doses/day); pretreatment with diphenhydramine will decrease risk of extrapyramidal reactions to this dosage

Chemotherapy-induced emesis (unlabeled use): I.V.: 1-2 mg/kg 30 minutes before chemotherapy and every 2-4 hours

Postpyloric feeding tube placement: I.V.:

<6 years: 0.1 mg/kg as a single dose

6-14 years: 2.5-5 mg as a single dose

>14 years: Refer to adult dosing.

Dosing: Geriatric

Initial: Dose at the lower end of the recommended range. Refer to adult dosing.

Dosing: Renal Impairment

Clcr <40 mL/minute: Administer 50% of normal dose.

Not dialyzable (0% to 5%); supplemental dose is not necessary